Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs

Tan, Emily L.C.; Ooi, Eng Eong; Lin, Chin-Yo; Tan, Hwee Cheng; Ling, Ai Ee; Lim, Bing; Stanton, Lawrence W.

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs

Published Date:

Apr 2004

Source:

Emerg Infect Dis. 10(4):581-586.

[PDF-131.59 KB]

Details:

Alternative Title:

Emerg Infect Dis

Personal Author:

Tan, Emily L.C. ; Ooi, Eng Eong ; Lin, Chin-Yo ; Tan, Hwee Cheng ; Ling, Ai Ee ; ... More ▼

Description:

Severe acute respiratory syndrome (SARS) is an infectious disease caused by a newly identified human coronavirus (SARS-CoV). Currently, no effective drug exists to treat SARS-CoV infection. In this study, we investigated whether a panel of commercially available antiviral drugs exhibit in vitro anti-SARS-CoV activity. A drug-screening assay that scores for virus-induced cytopathic effects on cultured cells was used. Tested were 19 clinically approved compounds from several major antiviral pharmacologic classes: nucleoside analogs, interferons, protease inhibitors, reverse transcriptase inhibitors, and neuraminidase inhibitors. Complete inhibition of cytopathic effects of SARS-CoV in culture was observed for interferon subtypes, b-1b, a-n1, a-n3, and human leukocyte interferon a. These findings support clinical testing of approved interferons for the treatment of SARS.

Subject:

[+]

Document Type:

Journal Article

Collection(s):

Emerging Infectious Diseases

Main Document Checksum:

[+]

Supporting Files:

	03-0458-F1.gif	image/gif
	03-0458-F1.jpg	image/jpeg
	03-0458-F2.gif	image/gif
	03-0458-F2.jpg	image/jpeg
	03-0458.nxml	text/plain
	license.txt	text/plain

No Related Documents.

You May Also Like:

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Personal Author:

Vincent, Martin J; Bergeron, Eric; Benjannet, Suzanne; Erickson, Bobbie R; Rollin, Pierre E; Ksiazek, Thomas G; Seidah, Nabil G; Nichol, Stuart T;

Published Date:

Aug 22 2005

Source:

Virol J. 2005; 2:69.

Description:

BackgroundSevere acute respiratory syndrome (SARS) is caused by a newly discovered coronavirus (SARS-CoV). No effective prophylactic or post-exposure therapy is currently available.ResultsWe report, however, that chloroquine has strong antiviral effe...

File Type:

[PDF - 847.81 KB]
Interferon-β 1a and SARS Coronavirus Replication

Personal Author:

Hensley, Lisa E.; Fritz, Elizabeth A.; Jahrling, Peter B.; Karp, Christopher; Huggins, John W.; Geisbert, Thomas W.;

Published Date:

Feb 2004

Source:

Emerg Infect Dis. 10(2):317-319.

Description:

A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effec...

File Type:

[PDF - 1.64 MB]
SARS: Systematic Review of Treatment Effects

Personal Author:

Stockman, Lauren J; Bellamy, Richard; Garner, Paul;

Published Date:

Sep 2006

Source:

PLoS Med. 2006; 3(9).

Description:

BackgroundThe SARS outbreak of 2002–2003 presented clinicians with a new, life-threatening disease for which they had no experience in treating and no research on the effectiveness of treatment options. The World Health Organization (WHO) expert pa...

File Type:

[PDF - 180.72 KB]
Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus

Personal Author:

Uyeki, Timothy M.; Erlandson, Karl J.; Korch, George; O’Hara, Michael; Wathen, Michael; Hu-Primmer, Jean; Hojvat, Sally; Stemmy, Erik J.; Donabedian, Armen;

Published Date:

July 15 2016

Source:

Emerg Infect Dis. 22(7)

Description:

Preclinical development of and research on potential Middle East respiratory syndrome coronavirus (MERS-CoV) medical countermeasures remain preliminary; advancements are needed before most countermeasures are ready to be tested in human clinical tria...

File Type:

[PDF - 1.46 MB]
Information for clinicians on therapeutic options for COVID-19 patients

Corporate Authors:

National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.

Published Date:

March 21, 2020

Series:

Coronavirus Disease 2019 (COVID-19)

Description:

There are no US Food and Drug Administration (FDA)-approved drugs specifically for the treatment of patients with COVID-19. At present clinical management includes infection prevention and control measures and supportive care, including supplementary...

File Type:

[PDF - 65.84 KB]